CXCL1 and coronary artery disorder: Our finding that the angiogenic chemokine CXCL1 was significantly higher in a small number of subjects not on statin therapy is consistent with a previously published paper where investigators found that in 8 subjects with coronary artery disease who were not on statin therapy at baseline, 6 months of high-dose atorvastatin treatment (80mg daily) was associated with a significant decrease in the gene expression of CXCL1 in their peripheral blood mononuclear cells [12].